JPWO2021182467A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021182467A5 JPWO2021182467A5 JP2022507218A JP2022507218A JPWO2021182467A5 JP WO2021182467 A5 JPWO2021182467 A5 JP WO2021182467A5 JP 2022507218 A JP2022507218 A JP 2022507218A JP 2022507218 A JP2022507218 A JP 2022507218A JP WO2021182467 A5 JPWO2021182467 A5 JP WO2021182467A5
- Authority
- JP
- Japan
- Prior art keywords
- polymer
- drug substance
- granules according
- component
- granules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920000642 polymer Polymers 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 11
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 7
- 229940088679 drug related substance Drugs 0.000 claims description 7
- 238000002844 melting Methods 0.000 claims description 7
- 230000008018 melting Effects 0.000 claims description 7
- 235000021355 Stearic acid Nutrition 0.000 claims description 4
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 4
- 239000008117 stearic acid Substances 0.000 claims description 4
- 229920002884 Laureth 4 Polymers 0.000 claims description 3
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims description 3
- 229920003147 ammonioalkyl methacrylate copolymer Polymers 0.000 claims description 3
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 3
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000009477 glass transition Effects 0.000 claims 1
- 239000000155 melt Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 4
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960004115 sitagliptin phosphate Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- RTZRUVMEWWPNRR-UHFFFAOYSA-N tert-butyl n-(3-iodo-1h-pyrrolo[2,3-b]pyridin-5-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CN=C2NC=C(I)C2=C1 RTZRUVMEWWPNRR-UHFFFAOYSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024029031A JP2024063111A (ja) | 2020-03-11 | 2024-02-28 | 顆粒及びそれを用いた製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062988083P | 2020-03-11 | 2020-03-11 | |
| US62/988,083 | 2020-03-11 | ||
| PCT/JP2021/009284 WO2021182467A1 (ja) | 2020-03-11 | 2021-03-09 | 顆粒及びそれを用いた製剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024029031A Division JP2024063111A (ja) | 2020-03-11 | 2024-02-28 | 顆粒及びそれを用いた製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2021182467A1 JPWO2021182467A1 (enExample) | 2021-09-16 |
| JPWO2021182467A5 true JPWO2021182467A5 (enExample) | 2022-11-08 |
| JP7487290B2 JP7487290B2 (ja) | 2024-05-20 |
Family
ID=77670617
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022507218A Active JP7487290B2 (ja) | 2020-03-11 | 2021-03-09 | 顆粒及びそれを用いた製剤 |
| JP2024029031A Withdrawn JP2024063111A (ja) | 2020-03-11 | 2024-02-28 | 顆粒及びそれを用いた製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024029031A Withdrawn JP2024063111A (ja) | 2020-03-11 | 2024-02-28 | 顆粒及びそれを用いた製剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230014578A1 (enExample) |
| EP (1) | EP4119129A4 (enExample) |
| JP (2) | JP7487290B2 (enExample) |
| KR (3) | KR20260059683A (enExample) |
| CN (1) | CN115209876A (enExample) |
| TW (1) | TWI850539B (enExample) |
| WO (1) | WO2021182467A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7817300B2 (ja) * | 2023-02-14 | 2026-02-18 | 沢井製薬株式会社 | コーティング顆粒、コーティング顆粒を含む製剤及びそれらの製造方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2915653B2 (ja) * | 1991-11-14 | 1999-07-05 | 第一製薬株式会社 | マスクされた粒状物 |
| JP3265680B2 (ja) * | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
| US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| UA80393C2 (uk) * | 2000-12-07 | 2007-09-25 | Алтана Фарма Аг | Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці |
| JP4310605B2 (ja) * | 2001-05-25 | 2009-08-12 | 大塚製薬株式会社 | 医薬用組成物 |
| CN1301104C (zh) * | 2002-02-21 | 2007-02-21 | 大塚制药株式会社 | 缓释制剂及其制造方法 |
| US8420115B2 (en) * | 2004-06-03 | 2013-04-16 | Taisho Pharmaceutical Co., Ltd. | Oral preparations and process for production thereof |
| US9884022B2 (en) * | 2010-04-07 | 2018-02-06 | Lupin Limited | Controlled release pharmaceutical compositions of tapentadol |
| FR2999937B1 (fr) * | 2012-12-21 | 2015-01-09 | Sanofi Sa | Unite solide a haute teneur en fexofenadine et son procede de preparation |
| JP2015054822A (ja) * | 2013-09-10 | 2015-03-23 | ニプロ株式会社 | クロピドグレル含有錠剤およびその製造方法 |
| CN109069460A (zh) * | 2016-05-09 | 2018-12-21 | 分散技术有限责任公司 | 改进的药物制剂 |
| JP2018083809A (ja) * | 2016-11-16 | 2018-05-31 | 沢井製薬株式会社 | シロドシン含有粒子の製造方法及びシロドシン含有口腔内崩壊錠の製造方法 |
| JP6895779B2 (ja) * | 2017-03-17 | 2021-06-30 | 東和薬品株式会社 | アジルサルタン含有固形医薬組成物 |
-
2021
- 2021-03-09 CN CN202180017989.5A patent/CN115209876A/zh active Pending
- 2021-03-09 EP EP21766854.0A patent/EP4119129A4/en active Pending
- 2021-03-09 JP JP2022507218A patent/JP7487290B2/ja active Active
- 2021-03-09 KR KR1020267012313A patent/KR20260059683A/ko active Pending
- 2021-03-09 KR KR1020267012314A patent/KR20260077761A/ko active Pending
- 2021-03-09 WO PCT/JP2021/009284 patent/WO2021182467A1/ja not_active Ceased
- 2021-03-09 KR KR1020227026916A patent/KR20220123689A/ko not_active Ceased
- 2021-03-10 TW TW110108516A patent/TWI850539B/zh active
-
2022
- 2022-09-12 US US17/942,333 patent/US20230014578A1/en active Pending
-
2024
- 2024-02-28 JP JP2024029031A patent/JP2024063111A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5443344B2 (ja) | タダラフィルを含む薬剤の製造の方法 | |
| CN103998037B (zh) | 对高熔点疏水性化合物具有改进的生物利用度的药物组合物 | |
| EP1166776A2 (de) | Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstofffreisetzung | |
| SI21394A2 (sl) | Farmacevtske pelete, ki vsebujejo tamsulozin | |
| CN107427504B (zh) | 癸氧喹酯固体分散体、其制备方法和用途 | |
| CN102218042A (zh) | 富马酸喹硫平组合物的缓释片剂及其制备方法 | |
| JP7738697B2 (ja) | 顆粒及びそれを用いた製剤 | |
| CA2797551A1 (en) | Melt-granulated fingolimod | |
| JP2024063111A (ja) | 顆粒及びそれを用いた製剤 | |
| Sawafta et al. | Impact of the manufacturing technique on the dissolution-enhancement functionality of PEG4000 in Cilostazol tablets | |
| CN105073101A (zh) | 具有高含量非索非那定的固体单元及其制备方法 | |
| JPWO2021182469A5 (enExample) | ||
| JPS62221626A (ja) | １，４−ジヒドロピリジン化合物の製剤用組成物 | |
| EP3731816B1 (en) | Solid oral pharmaceutical compositions comprising apixaban | |
| US20170173157A1 (en) | Method of manufacturing fine particles suitable for orally disintegrating pharmaceutical dosage forms | |
| HK40082230A (en) | Granules and preparation using same | |
| CN107007559B (zh) | 一种稳定的口服药物组合物及其制备方法 | |
| KR101798184B1 (ko) | 약물 방출제어용 조성물 | |
| KR101748215B1 (ko) | 경구용 서방성 제제 | |
| KR102065090B1 (ko) | 레베티라세탐 또는 이의 약제학적으로 허용되는 염을 함유하는 서방성 제제 및 이의 제조방법 | |
| JP2022062674A (ja) | 懸濁性顆粒及びそれを用いた懸濁用顆粒製剤 | |
| HK40081736A (en) | Granules and preparation using same | |
| CN107080740A (zh) | 一种用于制备口服缓释制剂的药用组合物 | |
| HK1196072A (en) | Pharmaceutical composition with improved bioavailability for high melting hydrophobic compound | |
| HK1196072B (en) | Pharmaceutical composition with improved bioavailability for high melting hydrophobic compound |